PSMA-Targeting Radiopharmaceutical Complex for Prostate Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PSMA-targeting compounds for prostate cancer treatment face challenges such as high kidney uptake with shorter-lived radionuclides like 212Pb, suboptimal biodistribution, and limited radiobiological effectiveness.
Innovation Solution
Development of a complex comprising a PSMA-targeting urea derivative linked to a radionuclide like 212Pb or 227Th via a chelating moiety, utilizing linkers such as DOTA or TCMC to adjust molecular properties and reduce kidney uptake.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If PSMA-617 is used with shorter-lived radionuclides like 212Pb, then the initial kidney uptake is high, but this represents a potential toxicity problem
Solution Approach 1:
The patent modifies molecular parameters by changing the chelator from DOTA to TCMC and adjusting the linker structure to optimize the compound's biodistribution properties. These parameter changes reduce kidney uptake while maintaining tumor targeting efficiency, resolving the contradiction between therapeutic effectiveness and kidney toxicity.
Solution Approach 2:
The invention creates a composite structure combining PSMA-targeting ligand, optimized linker, and TCMC chelator with radionuclide 212Pb. This composite radiopharmaceutical achieves improved biodistribution by integrating multiple functional components that work together to reduce kidney accumulation while maintaining high tumor uptake.
2Reliability
If current PSMA ligands are used, then tumor targeting is achieved, but radiobiological effectiveness is relatively low
Solution Approach 1:
The patent changes the radionuclide parameter from longer-lived isotopes to shorter-lived 212Pb (half-life 10.6 hours), which delivers higher radiation dose rate to tumors. This parameter change in radionuclide selection enhances radiobiological effectiveness while the optimized ligand structure maintains reliable tumor targeting.
3Productivity
If bone-seeker 223Ra is used, then skeletal metastases are targeted, but activity is limited to bone metastases and soft tissue metastases are not targeted
Solution Approach 1:
The patent creates a universal radiopharmaceutical platform using PSMA-targeting ligand with 212Pb that can treat both bone and soft tissue metastases. This multi-functional approach overcomes the limitation of bone-seekers like 223Ra by providing systemically active therapy that targets PSMA-expressing tumors regardless of tissue type or location.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed solution achieves reduced kidney uptake and improved tumor targeting, enhancing the therapeutic potential for prostate cancer, especially in treating both bone and soft tissue metastases.
Implementation Method 1
the compound X is linked to a radionuclide, such as 212Pb or 227Th, by a chelating moiety Z
Data Source
AI summary
The present invention relates to complexes comprising a prostate-specific membrane antigen (PSMA) targeting compound linked to a radionuclide, such as 212Pb or 227Th, through a TCMC or DOTA chelating moiety. These compounds, and pharmaceutical compositions comprising them, can be used for medical applications. These applications include the treatment of prostate cancer, and the complexes allow for dual targeting of cancers.